Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Danaher; Sequenom; Complete Genomics; PerkinElmer; GnuBio; Novozymes, Morphosys; OGI

NEW YORK (GenomeWeb News) – Danaher's board of directors approved a quarterly dividend of $.025 per share payable on Jan. 27, 2012 to holders of record on Dec. 30, 2011.

Sequenom said this week that it has been upgraded from the Nasdaq Global Market to the Nasdaq Global Select Market. It will continue to trade under the ticker symbol "SQNM" and will transfer its listing starting Jan. 3, 2012.

Complete Genomics has signed an agreement to sequence and contribute 500 human genomes to the 1000 Genomes Project, GenomeWeb Daily News sister publication In Sequence reported this week. Project organizers will choose the samples, which will be sequenced at a coverage of 40 times within a 12-month period.

The board of directors of PerkinElmer has declared a quarterly dividend of $.07 per share payable on Feb. 10, 2012 to holders of record at the close of business on Jan. 20, 2012.

GnuBio said this week that it has started building the beta version of its microfluidics-based sequencing system and is transitioning into the commercial phase of its business. It aims to launch the system, which will initially provide 1,000-base-pair reads, commercially in the second quarter of 2012.

Novozymes has licensed non-exclusive rights to use Morphosys' Slonomics technology to develop products for the industrial biotech sector.

The Ontario Genomics Institute has awarded two research facilities $10,000 each in technology seeding grants. The Centre for Applied Genomics at the Hospital for Sick Children in Toronto and StemCore Laboratories, based at the Ottawa Hospital Research Institute, received the awards. OGI said the funds will advance next-generation sequencing methods.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.